About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York State | 8,190 Studies Near You | Clareo Health

Clinical Trials LocationsNew York State

Clinical Trials in New York State

Discover 8,190 clinical trials near New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3641-3660 of 8,190 trials

COMPLETEDPhase 262 miles

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

NCT04747977

To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

Ocular Therapeutix, Inc.172 participantsStarted Feb 2021

Inglewood, California, United States • Mission Hills, California, United States • Newport Beach, California, United States +12 more locations

COMPLETEDPhase 364 miles

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines

Migraine, With or Without Aura

Pfizer1,499 participantsStarted Jul 2017

Mobile, Alabama, United States • Glendale, Arizona, United States • Rogers, Arkansas, United States +47 more locations

Find Trials by Condition in New York State

Breast Cancerin New York State Lung Cancerin New York State Prostate Cancerin New York State Colorectal Cancerin New York State Melanomain New York State Leukemiain New York State Lymphomain New York State Pancreatic Cancerin New York State Ovarian Cancerin New York State Brain Cancerin New York State

Data from ClinicalTrials.govTerms

COMPLETEDPhase 367 miles

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT03989232

This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance. Participants will inject semaglutide under the skin once a week. The study will last for about 49 weeks. Participants will have 9 clinic visits and 2 phone calls with the study doctor. At the visits participants will have blood taken and eye tests done. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period. Female participants who can get pregnant will be checked 11 times for pregnancy via urine tests.

Diabetes Mellitus, Type 2

Novo Nordisk A/S961 participantsStarted Jun 2019

Birmingham, Alabama, United States • Chandler, Arizona, United States • Glendale, Arizona, United States +126 more locations

COMPLETEDPhase 369 miles

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411

A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).

Postmenopausal Osteoporosis

Radius Health, Inc.511 participantsStarted Aug 2019

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Glendale, Arizona, United States +94 more locations

COMPLETEDPhase 386 miles

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

NCT01938001

This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.

Lymphoma, Non-Hodgkin

Celgene358 participantsStarted Nov 2013

Mobile, Alabama, United States • Glendale, Arizona, United States • Escondido, California, United States +157 more locations

COMPLETEDPhase 3107 miles

Coenzyme Q10 Phase III Trial in Gulf War Illness

NCT02865460

The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.

Gulf War IllnessChronic FatigueUbiquinol+1 more

VA Office of Research and Development100 participantsStarted Jul 2017

Miami, Florida, United States • Boston, Massachusetts, United States • Minneapolis, Minnesota, United States +1 more locations

COMPLETEDNA112 miles

A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM

NCT03167606

The proposed MyPEEPS Mobile intervention is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information specifically developed for at-risk young men who have sex with men (YMSM). This will be the one of the first studies to test the efficacy of a scaled-up, mobile version of an existing human immunodeficiency virus (HIV) prevention intervention originally developed for, designed by, and piloted for, a diverse group of YMSM. MyPEEPS Mobile will be tested in an randomized controlled trial with racially and ethnically diverse HIV-negative or unknown status YMSM aged 13-18 at four geographically diverse sites: Birmingham, Chicago, New York City, and Seattle, allowing for increased generalizability of findings.

Columbia University764 participantsStarted Jun 2018

Birmingham, Alabama, United States • Chicago, Illinois, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 2112 miles

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

NCT02921269

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise Specified+4 more

National Cancer Institute (NCI)11 participantsStarted Mar 2017

Los Angeles, California, United States • Los Angeles, California, United States • Pasadena, California, United States +19 more locations

COMPLETEDPhase 2112 miles

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

NCT03452228

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.

Severe Hypertriglyceridemia (sHTG)

Regeneron Pharmaceuticals52 participantsStarted Jun 2018

Boca Raton, Florida, United States • Atlanta, Georgia, United States • Kansas City, Kansas, United States +14 more locations

COMPLETEDPhase 3112 miles

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298

This study aims to determine whether the injection of botulinum toxin A or placebo (unpreserved 0.9% sodium chloride) into the masseter and temporalis muscles provides pain relief and improved jaw function in those who suffer from myofascial pain disorder. The study hypothesis is that botulinum toxin A injection is superior to placebo. The specific research questions are: 1. Is the injection of botulinum toxin A superior to placebo for the improvement in pain? 2. Is the injection of botulinum toxin A superior to placebo for the improvement in function or quality of life (QOL)? 3. Are there any adverse effects that result from injection of botulinum toxin A or placebo into the masseters and temporalis muscles? Limited data exists to support the use of botulinum toxin A in the management of myofascial pain disorder of the masticatory region. Botulinum toxin A is not FDA approved for intra-muscular injection within the masticatory region. Its use in the masticatory region is considered off-label but performed without significant known complications. This study will provide the opportunity to quantitate and qualitate any complications in a large prospective sample of patients.

Pain, HeadPain SyndromeTemporomandibular Disorder+2 more

Weill Medical College of Cornell University75 participantsStarted Aug 2018

Chicago, Illinois, United States • New York, New York, United States

COMPLETEDPhase 1119 miles

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

NCT03589651

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

Unresectable or Metastatic Solid Tumors

Incyte Corporation83 participantsStarted Aug 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Gainesville, Florida, United States +6 more locations

TERMINATEDPhase 1120 miles

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710

A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types

Bristol-Myers Squibb21 participantsStarted Jun 2020

Hartford, Connecticut, United States • Fort Wayne, Indiana, United States • Naples, Italy +3 more locations

COMPLETEDPhase 1/2120 miles

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

NCT03303339

The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or are ineligible for intensive induction therapy, and to determine the maximum tolerated dose and recommended phase 2 dose of Onvansertib in combination with decitabine or Onvansertib in combination with low-dose cytarabine. In the phase 2 portion of the study, Onvansertib in combination with decitabine will be studied to provide further data on the safety profile of the combination and to preliminarily assess the activity of the chosen combination in patients with untreated AML who are not candidates for aggressive induction therapy, or who have received one prior treatment for their AML.

Acute Myeloid Leukemia

Cardiff Oncology72 participantsStarted Nov 2017

Los Angeles, California, United States • New Haven, Connecticut, United States • Westwood, Kansas, United States +6 more locations

COMPLETED127 miles

Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection

NCT04169815

The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.

Beckman Coulter, Inc.2,370 participantsStarted Nov 2019

Loma Linda, California, United States • Sacramento, California, United States • Gainesville, Florida, United States +12 more locations

TERMINATEDPhase 3153 miles

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.

COVID-19CoronavirusCoronavirus Infection

Bellerophon Pulse Technologies191 participantsStarted Jul 2020

Phoenix, Arizona, United States • San Diego, California, United States • San Diego, California, United States +14 more locations

COMPLETEDPhase 2/3170 miles

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

NCT01818492

The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. Administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.

Primary Haemophagocytic Lymphohistiocytosis

Swedish Orphan Biovitrum45 participantsStarted Jul 2013

Aurora, Colorado, United States • Wilmington, Delaware, United States • Atlanta, Georgia, United States +17 more locations

TERMINATEDPhase 1199 miles

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

NCT03906526

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). Subjects with previously untreated, resectable SCCHN, will be recruited onto this trial and will initially undergo pre-treatment diagnostic imaging and biological sample collection. These subjects will undergo pre-operative study treatment for a 3 to 4-week period prior to a scheduled surgical resection.

Carcinoma, Squamous Cell

Celgene15 participantsStarted Jul 2019

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Boston, Massachusetts, United States +9 more locations

TERMINATEDPhase 1200 miles

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058

This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with doxorubicin, docetaxel, and cyclophosphamide (TAC). Chemotherapy affects cells that are dividing, whether they are tumor cells or healthy cells (including, bone marrow cells, hair follicle cells, and epithelial cells lining the gastrointestinal tract). ALRN-6924 is designed to stop cell division in healthy cells but not in tumor cells because they have a mutation of the TP53 gene. When this happens, tumor cells will still be destroyed by the chemotherapy but healthy cells that are not dividing may be spared from chemotherapy damage and the patient should have less side effects.

Prevention of Chemotherapy-induced Myelosuppression

Aileron Therapeutics, Inc.6 participantsStarted Jan 2023

Tamarac, Florida, United States • Huntersville, North Carolina, United States • Wilson, North Carolina, United States +11 more locations

COMPLETED247 miles

Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes

NCT00342667

A major goal of modern perinatal and neonatal medicine is to reduce the rate of developmental disabilities, especially mental retardation. Cerebral palsy is frequently associated with neurologic abnormalities and mental retardation. Improvements in neonatal intensive care have resulted in improved survival of very low birthweight infants but also in an increased frequency of cerebral palsy. Prematurity is a leading risk factor for cerebral palsy. Two thirds of preterm neonates are born to mothers with preterm labor with intact membranes or preterm premature rupture of membranes. A growing body of evidence suggests that these conditions are heterogeneous. This is an observational cohort study designed to identify the mechanisms of disease in patients with preterm labor/contractions and preterm premature rupture of membranes and to describe the relationship between clinical, biochemical, histological, biophysical parameters and the development of infant neurological disorders.

Preterm BirthPregnancy

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)4,673 participantsStarted Dec 1997

Bethesda, Maryland, United States • Detroit, Michigan, United States • Puente Alto, Chile +2 more locations

COMPLETED414 miles

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

NCT00342277

The understanding of the biological mechanisms underlying preterm birth is very limited, making prevention of preterm birth difficult. The incidence of preterm birth worldwide varies between 6%-11% in singleton pregnancies, and 64-93% of preterm deliveries occur after the spontaneous onset of labor (preterm labor). The risk factors associated with preterm birth include demographic variables such as ethnic group, past obstetric history, and complications of the current pregnancy such as infection and fetal congenital anomalies. The current study aims to investigate the basic mechanisms of preterm labor by systematically cataloging the changes in expression levels of all expressed genes whose sequences are available. The goals will be accomplished by using microarray technology followed by subsequent confirmative or complementary analyses.

Preterm BirthPremature Rupture of Membranes

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)6,838 participantsStarted Dec 1999

Detroit, Michigan, United States • Puente Alto, Chile • Padua, Italy +1 more locations

PreviousPage 183 of 410Next

Diabetes

in New York State

Heart Diseasein New York State